Consequences of Discontinuing a 4/6 Cyclin D-Dependent Kinase Inhibitor During Endocrine Treatment in Hormone-Sensitive Metastatic Breast Cancer Patients in the Context of the COVID-19 Outbreak.
Fiche publication
Date publication
octobre 2022
Journal
Clinical breast cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr LIMACHER Jean-Marc, Pr PETIT Thierry, Pr VELTEN Michel
Tous les auteurs :
Martin S, Pflumio C, Trensz P, Schaff-Wendling F, Weindling MK, Fischbach C, Pierard L, Limacher JM, Nader R, Velten M, Petit T
Lien Pubmed
Résumé
The impact of some hasty medical decision made during the first wave of the Coronavirus Disease 2019 (COVID-19) remains unknown. We have evaluated the consequences of one of these precautionary measures: the withdrawal of the cyclin D-dependent kinases 4/6 inhibitor (CDK4/6i) in patients whose metastatic disease was controlled by a combination of endocrine treatment and CDK 4/6i.
Mots clés
CDK4/6 inhibitors, COVID-19, Disease progression, Hepatic metastases, Treatment withdrawn
Référence
Clin Breast Cancer. 2022 10 13;: